Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $40.00 Consensus PT from Analysts

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has earned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $40.00.

ZLAB has been the subject of several research reports. Weiss Ratings upgraded shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Zacks Research upgraded shares of Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Citigroup decreased their target price on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research note on Friday, May 8th.

Insider Transactions at Zai Lab

In related news, CEO Ying Du sold 50,000 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $20.09, for a total transaction of $1,004,500.00. Following the completion of the sale, the chief executive officer directly owned 1,122,626 shares in the company, valued at approximately $22,553,556.34. This trade represents a 4.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William Lis sold 7,040 shares of Zai Lab stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $18.09, for a total value of $127,353.60. Following the sale, the director directly owned 50,437 shares of the company’s stock, valued at approximately $912,405.33. The trade was a 12.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 90,873 shares of company stock valued at $1,730,096. 4.88% of the stock is owned by insiders.

Institutional Investors Weigh In On Zai Lab

A hedge fund recently raised its position in Zai Lab stock. SG Americas Securities LLC lifted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 41.65% of the company’s stock.

Zai Lab Trading Up 13.7%

Shares of Zai Lab stock opened at $20.88 on Tuesday. Zai Lab has a 1 year low of $15.96 and a 1 year high of $36.77. The company has a market cap of $2.38 billion, a P/E ratio of -12.89 and a beta of 0.78. The stock has a 50-day moving average price of $18.64 and a 200 day moving average price of $19.22.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. The business had revenue of $106.31 million for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. On average, equities analysts forecast that Zai Lab will post -2.23 earnings per share for the current fiscal year.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.